Haemonetics Corporation (HAE) - Net Assets
Based on the latest financial reports, Haemonetics Corporation (HAE) has net assets worth $796.32 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.40 Billion) and total liabilities ($1.60 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Haemonetics Corporation to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $796.32 Million |
| % of Total Assets | 33.24% |
| Annual Growth Rate | 6.96% |
| 5-Year Change | 19.26% |
| 10-Year Change | 20.84% |
| Growth Volatility | 13.04 |
Haemonetics Corporation - Net Assets Trend (1992–2026)
This chart illustrates how Haemonetics Corporation's net assets have evolved over time, based on quarterly financial data. Also explore Haemonetics Corporation asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Haemonetics Corporation (1992–2026)
The table below shows the annual net assets of Haemonetics Corporation from 1992 to 2026. For live valuation and market cap data, see how much is Haemonetics Corporation worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $893.76 Million | +8.88% |
| 2025-03-31 | $820.84 Million | -14.49% |
| 2024-03-31 | $959.96 Million | +17.35% |
| 2023-03-31 | $818.00 Million | +9.15% |
| 2022-03-31 | $749.42 Million | +2.43% |
| 2021-03-31 | $731.67 Million | +24.62% |
| 2020-03-31 | $587.11 Million | -12.09% |
| 2019-03-31 | $667.87 Million | -11.24% |
| 2018-03-31 | $752.43 Million | +1.73% |
| 2017-03-31 | $739.61 Million | +2.73% |
| 2016-03-31 | $719.98 Million | -12.85% |
| 2015-03-31 | $826.12 Million | -1.61% |
| 2014-03-31 | $839.61 Million | +9.16% |
| 2013-03-31 | $769.18 Million | +4.64% |
| 2012-03-31 | $735.08 Million | +7.13% |
| 2011-03-31 | $686.14 Million | +15.68% |
| 2010-03-31 | $593.12 Million | +9.86% |
| 2009-03-31 | $539.88 Million | +9.25% |
| 2008-03-31 | $494.19 Million | +3.03% |
| 2007-03-31 | $479.65 Million | +8.60% |
| 2006-03-31 | $441.65 Million | +24.36% |
| 2005-03-31 | $355.13 Million | +26.95% |
| 2004-03-31 | $279.75 Million | +25.31% |
| 2003-03-31 | $223.24 Million | -5.74% |
| 2002-03-31 | $236.82 Million | +9.89% |
| 2001-03-31 | $215.52 Million | +4.39% |
| 2000-03-31 | $206.44 Million | -6.97% |
| 1999-03-31 | $221.90 Million | +13.97% |
| 1998-03-31 | $194.70 Million | -13.58% |
| 1997-03-31 | $225.30 Million | +3.82% |
| 1996-03-31 | $217.00 Million | +12.32% |
| 1995-03-31 | $193.20 Million | +20.15% |
| 1994-03-31 | $160.80 Million | +26.91% |
| 1993-03-31 | $126.70 Million | +39.85% |
| 1992-03-31 | $90.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Haemonetics Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $893.76 Million | 100.00% |
| Total Equity | $893.76 Million | 100.00% |
Haemonetics Corporation Competitors by Market Cap
The table below lists competitors of Haemonetics Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hub Group Inc
NASDAQ:HUBG
|
$2.43 Billion |
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
$2.43 Billion |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
$2.43 Billion |
|
Jiangsu Lihua Animal Husbandry Co Ltd
SHE:300761
|
$2.43 Billion |
|
Elekta AB (publ)
ST:EKTA-B
|
$2.43 Billion |
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
$2.43 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
$2.43 Billion |
|
Levi Strauss & Co Class A
NYSE:LEVI
|
$2.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Haemonetics Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 820,836,000 to 893,761,000, a change of 72,925,000 (8.9%).
- Net income of 97,308,000 contributed positively to equity growth.
- Share repurchases of 175,000,000 reduced equity.
- Other comprehensive income increased equity by 55,084,000.
- Other factors increased equity by 95,533,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $97.31 Million | +10.89% |
| Share Repurchases | $175.00 Million | -19.58% |
| Other Comprehensive Income | $55.08 Million | +6.16% |
| Other Changes | $95.53 Million | +10.69% |
| Total Change | $- | 8.88% |
Book Value vs Market Value Analysis
This analysis compares Haemonetics Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.36x to 3.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-03-31 | $1.59 | $67.16 | x |
| 1993-03-31 | $2.22 | $67.16 | x |
| 1994-03-31 | $2.78 | $67.16 | x |
| 1995-03-31 | $3.39 | $67.16 | x |
| 1996-03-31 | $3.93 | $67.16 | x |
| 1997-03-31 | $4.11 | $67.16 | x |
| 1998-03-31 | $3.65 | $67.16 | x |
| 1999-03-31 | $4.13 | $67.16 | x |
| 2000-03-31 | $3.90 | $67.16 | x |
| 2001-03-31 | $4.14 | $67.16 | x |
| 2002-03-31 | $4.36 | $67.16 | x |
| 2003-03-31 | $4.46 | $67.16 | x |
| 2004-03-31 | $5.68 | $67.16 | x |
| 2005-03-31 | $6.72 | $67.16 | x |
| 2006-03-31 | $8.04 | $67.16 | x |
| 2007-03-31 | $8.67 | $67.16 | x |
| 2008-03-31 | $9.24 | $67.16 | x |
| 2009-03-31 | $10.31 | $67.16 | x |
| 2010-03-31 | $11.38 | $67.16 | x |
| 2011-03-31 | $13.40 | $67.16 | x |
| 2012-03-31 | $14.25 | $67.16 | x |
| 2013-03-31 | $14.72 | $67.16 | x |
| 2014-03-31 | $16.03 | $67.16 | x |
| 2015-03-31 | $15.86 | $67.16 | x |
| 2016-03-31 | $14.14 | $67.16 | x |
| 2017-03-31 | $14.35 | $67.16 | x |
| 2018-03-31 | $14.06 | $67.16 | x |
| 2019-03-31 | $12.62 | $67.16 | x |
| 2020-03-31 | $11.33 | $67.16 | x |
| 2021-03-31 | $14.26 | $67.16 | x |
| 2022-03-31 | $14.59 | $67.16 | x |
| 2023-03-31 | $15.91 | $67.16 | x |
| 2024-03-31 | $18.68 | $67.16 | x |
| 2025-03-31 | $16.18 | $67.16 | x |
| 2026-03-31 | $18.87 | $67.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Haemonetics Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.89%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.29%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.68x
- Recent ROE (10.89%) is above the historical average (9.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | 19.87% | 10.20% | 1.22x | 1.60x | $8.94 Million |
| 1993 | 19.57% | 11.47% | 1.20x | 1.42x | $12.13 Million |
| 1994 | 19.59% | 12.68% | 1.08x | 1.43x | $15.42 Million |
| 1995 | 17.39% | 12.80% | 0.94x | 1.45x | $14.28 Million |
| 1996 | 16.54% | 12.90% | 0.97x | 1.33x | $14.20 Million |
| 1997 | 14.65% | 10.65% | 0.96x | 1.44x | $10.47 Million |
| 1998 | -12.74% | -8.68% | 0.85x | 1.73x | $-44.27 Million |
| 1999 | 9.51% | 7.48% | 0.79x | 1.61x | $-1.09 Million |
| 2000 | 9.20% | 6.84% | 0.80x | 1.69x | $-1.65 Million |
| 2001 | 3.36% | 2.46% | 0.85x | 1.60x | $-14.32 Million |
| 2002 | 12.68% | 9.38% | 0.88x | 1.54x | $6.34 Million |
| 2003 | 12.71% | 8.42% | 0.94x | 1.61x | $6.06 Million |
| 2004 | 10.48% | 8.05% | 0.89x | 1.46x | $1.35 Million |
| 2005 | 11.16% | 10.33% | 0.82x | 1.32x | $4.13 Million |
| 2006 | 15.64% | 16.46% | 0.77x | 1.24x | $24.91 Million |
| 2007 | 10.24% | 10.92% | 0.79x | 1.19x | $1.14 Million |
| 2008 | 10.52% | 10.07% | 0.85x | 1.23x | $2.56 Million |
| 2009 | 10.98% | 9.92% | 0.92x | 1.20x | $5.32 Million |
| 2010 | 9.84% | 9.04% | 0.86x | 1.27x | $-937.40K |
| 2011 | 11.66% | 11.82% | 0.81x | 1.21x | $11.37 Million |
| 2012 | 9.10% | 9.19% | 0.80x | 1.24x | $-6.62 Million |
| 2013 | 5.04% | 4.35% | 0.61x | 1.90x | $-38.12 Million |
| 2014 | 4.19% | 3.75% | 0.62x | 1.81x | $-48.81 Million |
| 2015 | 2.05% | 1.86% | 0.61x | 1.80x | $-65.72 Million |
| 2016 | -7.73% | -6.12% | 0.69x | 1.83x | $-127.62 Million |
| 2017 | -3.55% | -2.96% | 0.72x | 1.67x | $-100.23 Million |
| 2018 | 6.06% | 5.04% | 0.73x | 1.64x | $-29.67 Million |
| 2019 | 8.24% | 5.69% | 0.76x | 1.91x | $-11.77 Million |
| 2020 | 13.03% | 7.74% | 0.78x | 2.16x | $17.82 Million |
| 2021 | 10.86% | 9.13% | 0.48x | 2.49x | $6.30 Million |
| 2022 | 5.79% | 4.37% | 0.53x | 2.48x | $-31.57 Million |
| 2023 | 14.11% | 9.87% | 0.60x | 2.37x | $33.60 Million |
| 2024 | 12.25% | 8.98% | 0.60x | 2.29x | $21.56 Million |
| 2025 | 20.43% | 12.32% | 0.56x | 2.99x | $85.60 Million |
| 2026 | 10.89% | 7.29% | 0.56x | 2.68x | $7.93 Million |
Industry Comparison
This section compares Haemonetics Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,884,446,440
- Average return on equity (ROE) among peers: -48.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Haemonetics Corporation (HAE) | $796.32 Million | 19.87% | 2.01x | $2.43 Billion |
| Abbott Laboratories (ABT) | $26.81 Billion | 22.24% | 1.51x | $148.99 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $17.10 Million |
| Aethlon Medical Inc (AEMD) | $5.12 Million | -261.31% | 0.44x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $10.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $9.82 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $3.99 Million |
| Artivion Inc (AORT) | $24.90 Million | 15.66% | 0.41x | $1.10 Billion |
| Apyx Medical Inc (APYX) | $6.39 Million | 7.83% | 0.24x | $153.68 Million |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more